These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 25785753)

  • 41. Biomaterials-Enhanced Intranasal Delivery of Drugs as a Direct Route for Brain Targeting.
    Marcello E; Chiono V
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834804
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Focused Ultrasound-Mediated Intranasal Brain Drug Delivery Technique (FUSIN).
    Ye D; Chen H
    Methods Mol Biol; 2022; 2394():501-513. PubMed ID: 35094343
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Intranasal Nose-to-Brain Drug Delivery via the Olfactory Region in Mice: Two In-Depth Protocols for Region-Specific Intranasal Application of Antibodies and for Expression Analysis of Fc Receptors via In Situ Hybridization in the Nasal Mucosa.
    Herzog H; Glöckler S; Flamm J; Ladel S; Maigler F; Pitzer C; Schindowski K
    Methods Mol Biol; 2024; 2754():387-410. PubMed ID: 38512678
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evolving Drug Delivery Strategies to Overcome the Blood Brain Barrier.
    Hersh DS; Wadajkar AS; Roberts N; Perez JG; Connolly NP; Frenkel V; Winkles JA; Woodworth GF; Kim AJ
    Curr Pharm Des; 2016; 22(9):1177-1193. PubMed ID: 26685681
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Drug delivery in overcoming the blood-brain barrier: role of nasal mucosal grafting.
    Marianecci C; Rinaldi F; Hanieh PN; Di Marzio L; Paolino D; Carafa M
    Drug Des Devel Ther; 2017; 11():325-335. PubMed ID: 28184152
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nanotechnology for enhanced nose-to-brain drug delivery in treating neurological diseases.
    Huang Q; Chen Y; Zhang W; Xia X; Li H; Qin M; Gao H
    J Control Release; 2024 Feb; 366():519-534. PubMed ID: 38182059
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Olfactory targeting through intranasal delivery of biopharmaceutical drugs to the brain: current development.
    Wen MM
    Discov Med; 2011 Jun; 11(61):497-503. PubMed ID: 21712015
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Sellar Defect Reconstruction with Vascularized Superior Turbinate Mucosal Flaps in Endonasal Endoscopic Transsellar Approach.
    Kutlay M; Durmaz O; Kırık A; Yaşar S; Özer İ; Ezgü MC; Kural C; Temiz Ç; Durmaz A; Daneyemez MK; Izci Y
    World Neurosurg; 2020 Jan; 133():e503-e512. PubMed ID: 31550544
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Minimally Invasive Nasal Depot (MIND) technique for direct BDNF AntagoNAT delivery to the brain.
    Padmakumar S; Jones G; Pawar G; Khorkova O; Hsiao J; Kim J; Amiji MM; Bleier BS
    J Control Release; 2021 Mar; 331():176-186. PubMed ID: 33484777
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Nose-to-brain Delivery of Natural Compounds for the Treatment of Central Nervous System Disorders.
    Bicker J; Fortuna A; Alves G; Falcão A
    Curr Pharm Des; 2020; 26(5):594-619. PubMed ID: 31939728
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Formulation considerations for improving intranasal delivery of CNS acting therapeutics.
    Patel D; Thakkar H
    Ther Deliv; 2022 Jul; 13(7):371-381. PubMed ID: 36416617
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Intrathecal drug delivery in the era of nanomedicine.
    Fowler MJ; Cotter JD; Knight BE; Sevick-Muraca EM; Sandberg DI; Sirianni RW
    Adv Drug Deliv Rev; 2020; 165-166():77-95. PubMed ID: 32142739
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The prescription design and key properties of nasal gel for CNS drug delivery: A review.
    Wang M; Ma X; Zong S; Su Y; Su R; Zhang H; Liu Y; Wang C; Li Y
    Eur J Pharm Sci; 2024 Jan; 192():106623. PubMed ID: 37890640
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Permeabilization of the blood-brain barrier via mucosal engrafting: implications for drug delivery to the brain.
    Bleier BS; Kohman RE; Feldman RE; Ramanlal S; Han X
    PLoS One; 2013; 8(4):e61694. PubMed ID: 23637885
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of direct transport pathways of glycine receptor antagonists and an angiotensin antagonist from the nasal cavity to the central nervous system in the rat model.
    Charlton ST; Whetstone J; Fayinka ST; Read KD; Illum L; Davis SS
    Pharm Res; 2008 Jul; 25(7):1531-43. PubMed ID: 18293062
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Direct nose to brain delivery of small molecules: critical analysis of data from a standardized
    Dhuyvetter D; Tekle F; Nazarov M; Vreeken RJ; Borghys H; Rombouts F; Lenaerts I; Bottelbergs A
    Drug Deliv; 2020 Dec; 27(1):1597-1607. PubMed ID: 33169635
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Tailoring Formulations for Intranasal Nose-to-Brain Delivery: A Review on Architecture, Physico-Chemical Characteristics and Mucociliary Clearance of the Nasal Olfactory Mucosa.
    Gänger S; Schindowski K
    Pharmaceutics; 2018 Aug; 10(3):. PubMed ID: 30081536
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities.
    Begley DJ
    Pharmacol Ther; 2004 Oct; 104(1):29-45. PubMed ID: 15500907
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Intranasal drug delivery for brain targeting.
    Vyas TK; Shahiwala A; Marathe S; Misra A
    Curr Drug Deliv; 2005 Apr; 2(2):165-75. PubMed ID: 16305417
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The barrier and interface mechanisms of the brain barrier, and brain drug delivery.
    Zhang S; Gan L; Cao F; Wang H; Gong P; Ma C; Ren L; Lin Y; Lin X
    Brain Res Bull; 2022 Nov; 190():69-83. PubMed ID: 36162603
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.